BridgeBio Pharma BBIO Transfers to noncontrolling interests
Transfers to noncontrolling interests at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's transfers to noncontrolling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's transfers to noncontrolling interests?
- BridgeBio Pharma (BBIO) reported transfers to noncontrolling interests of -$1.96M in Q1 2026.
- How has BridgeBio Pharma's transfers to noncontrolling interests changed year-over-year?
- BridgeBio Pharma's transfers to noncontrolling interests decreased by 137.3% year-over-year, from -$824K to -$1.96M.
- What is the long-term trend for BridgeBio Pharma's transfers to noncontrolling interests?
- Over 4 years (2021 to 2025), BridgeBio Pharma's transfers to noncontrolling interests has grown at a 27.4% compound annual growth rate (CAGR), from -$2.12M to -$5.59M.
- What does transfers to noncontrolling interests mean?
- The net movement of funds or assets between the company and minority stakeholders in its subsidiaries.
- How do you interpret transfers to noncontrolling interests?
- An increase in transfers to noncontrolling interests may indicate higher distributions or capital support provided to minority partners, while a decrease may suggest reduced obligations or capital inflows from these partners.
- How does transfers to noncontrolling interests compare across companies?
- Commonly reported by companies with complex subsidiary structures or joint ventures, where minority interest accounting is required under GAAP.